These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566 [TBL] [Abstract][Full Text] [Related]
3. Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. Blanc Mettral J; Faller N; Cruchon S; Sottas L; Buclin T; Schild L; Choong E; Nahimana A; Decosterd LA Drug Metab Lett; 2019; 13(2):102-110. PubMed ID: 30734690 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Wasson CW; Abignano G; Hermes H; Malaab M; Ross RL; Jimenez SA; Chang HY; Feghali-Bostwick CA; Del Galdo F Ann Rheum Dis; 2020 Apr; 79(4):507-517. PubMed ID: 32041748 [TBL] [Abstract][Full Text] [Related]
13. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis. Ishibuchi H; Abe M; Yokoyama Y; Ishikawa O Exp Dermatol; 2010 Aug; 19(8):e111-6. PubMed ID: 20653770 [TBL] [Abstract][Full Text] [Related]
14. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts. Karimizadeh E; Motamed N; Mahmoudi M; Jafarinejad-Farsangi S; Jamshidi A; Faridani H; Gharibdoost F Arch Dermatol Res; 2015 Mar; 307(2):135-42. PubMed ID: 25527259 [TBL] [Abstract][Full Text] [Related]
15. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. Makino K; Jinnin M; Aoi J; Hirano A; Kajihara I; Makino T; Sakai K; Fukushima S; Inoue Y; Ihn H J Invest Dermatol; 2013 Jan; 133(1):110-9. PubMed ID: 22832484 [TBL] [Abstract][Full Text] [Related]
16. Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. Schmidt-Lauber C; Harrach S; Pap T; Fischer M; Victor M; Heitzmann M; Hansen U; Fobker M; Brand SM; Sindic A; Pavenstädt H; Edemir B; Schlatter E; Bertrand J; Ciarimboli G PLoS One; 2012; 7(12):e52247. PubMed ID: 23284953 [TBL] [Abstract][Full Text] [Related]
17. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472 [TBL] [Abstract][Full Text] [Related]
18. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Iwayama T; Olson LE Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576 [TBL] [Abstract][Full Text] [Related]
19. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]